CD19 and neoplasm: In vivo anti-tumor activity of the advanced panel of CAR and pCAR T-cells was compared with the commonly used CD19+ Nalm-6 xenograft model of B-cell acute lymphoblastic leukemia (B-ALL), using BLI to monitor disease status.